Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 15, Issue 9, Pages 1113-1126Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728222.2011.594438
Keywords
angiogenesis; metastasis; osteopontin; prognostic marker; targeted therapy; tumour-stroma interaction
Categories
Funding
- Department of Biotechnology
- Department of Science and Technology
- Council of Scientific and Industrial Research, Government of India
Ask authors/readers for more resources
Introduction: Cancer is an extremely complex disease and most cancer treatments are limited to chemotherapy, radiation and surgery. The progression of tumours towards malignancy requires the interaction of various cytokines, growth factors, transcription factors and effector molecules. Osteopontin is a cytokine-like, calcium-binding, extracelular-matrix-associated member of the small integrin-binding ligand, N-linked glycoprotein (SIBLING) family of proteins. It plays an important role in determining the oncogenic potential of various cancers. The role of osteopontin in various pathophysiological conditions suggests that the alteration in post-translationalmodification result in different functional forms that might change its normal physiological functions. Areas covered: Osteopontin-based anticancer therapy, which may provide a new insight for the effective management of cancer. Expert opinion: A better understanding of the signalling mechanism by which osteopontin promotes tumourigenesis may be useful in crafting novel osteopontin-based anticancer therapy. The role of osteopontin in promoting cancer progression is the subject of in depth investigation and thus targeting osteopontin might be a suitable therapeutic approach for the treatment of cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available